Vickie Bowcut
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vickie Bowcut has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Allan Hebbert
Mirati Therapeutics, Inc 92121 San Diego CA USA
54 shared publications - Christopher R. Smith
Mirati Therapeutics, Inc 92121 San Diego CA USA
54 shared publications - Darin Vanderpool
Mirati Therapeutics, Inc 92121 San Diego CA USA
54 shared publications - David M. Briere
Mirati Therapeutics (United States), San Diego, CA, United States
54 shared publications - J. David Lawson
Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States
54 shared publications - James G. Christensen
Mirati Therapeutics, San Diego, California
54 shared publications
Latest Publications
- Open Access
Chemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
Open AccessChemical Genetic Targeting of the LRRK2 GTPase Domain
Genetic variants throughout the multi-domain protein leucine-rich repeat kinase 2 ( LRRK2) gene are the most common cause of autosomal dominant Parkinson’s disease, and the most prevalent Parkinson’s-associated LRRK2 variants enhance kinase activity. Hence, the kinase domain has been extensively targeted for therapeutic development. However, clinical progression of LRRK2 kinase inhibitors has been limited by on-target peripheral toxicities linked to strong kinase suppression, raising the question of whether targeting LRRK2 kinase activity through other means could offer a more tunable therapeutic window. LRRK2 is one of two proteins in the human proteome that possess a Roc-COR GTPase domain in tandem with a kinase domain, and the GTPase domain has been shown to intramolecularly regulate kinase output. Here, we ask whether the Roc-COR GTPase can be targeted as an alternative approach to downregulate kinase activity. We utilize a chemical genetic approach to sensitize LRRK2 to existing GTPase inhibitors and show that pharmacologically engaging the Roc-COR GTPase domain in cells decreases but does not fully inhibit LRRK2-mediated Rab10 T73 phosphorylation. This study lays the groundwork for future efforts directed at the development of pharmacological inhibitors for the LRRK2 GTPase, providing an alternative approach for therapies targeting LRRK2-driven Parkinson’s disease.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S2 shows the antitumor activity of MRTX0902 in the LN229 (PTPN11 A72S-mutant) model, with tumor growth inhibition data displayed in Figure S2A and ERK phosphorylation graphed in Figure S2B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S2 shows the antitumor activity of MRTX0902 in the LN229 (PTPN11 A72S-mutant) model, with tumor growth inhibition data displayed in Figure S2A and ERK phosphorylation graphed in Figure S2B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines in vitro and in vivo.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S1 details the genetic vulnerabilities and modifiers of response associated with combination treatment of MRTX0902 with adagrasib in the KRAS G12C-mutant MIA PaCa-2 (S1A, S1B, S1D, and S1E) and LU99 (S1C) cell lines in vitro and in vivo.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S8 details the antitumor effects associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S1 details the efficacy of MRTX0902 in a panel of cancer cell lines.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Materials and Methods section includes detailed protocols for the following: Experimental Preparation of MRTX0902 and Avutometinib, SOS1 Biochemical Binding Assay, SOS1 and SOS2 Functional Assays, KRAS-SOS1 Protein-Protiein Interaction (PPI) HTRF Assay, In-Cell Western Assay, 3D Ultra-Low Attachment (ULA) Viability Assay, Immunoblotting and Densitometry Analysis, DUSP6 Quantification from Naive and Tumor-Bearing Mouse Blood, Bioanalysis and Pharmacokinetic Analysis, Synergy Analysis, CRISPR/Cas9 Screening and Data Analysis Methodology, RNAseq Pre-Processing, RNAseq Data Analysis, and Whole Genome Sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Materials and Methods section includes detailed protocols for the following: Experimental Preparation of MRTX0902 and Avutometinib, SOS1 Biochemical Binding Assay, SOS1 and SOS2 Functional Assays, KRAS-SOS1 Protein-Protiein Interaction (PPI) HTRF Assay, In-Cell Western Assay, 3D Ultra-Low Attachment (ULA) Viability Assay, Immunoblotting and Densitometry Analysis, DUSP6 Quantification from Naive and Tumor-Bearing Mouse Blood, Bioanalysis and Pharmacokinetic Analysis, Synergy Analysis, CRISPR/Cas9 Screening and Data Analysis Methodology, RNAseq Pre-Processing, RNAseq Data Analysis, and Whole Genome Sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S6 details the improved antiproliferative activity observed with the MRTX0902/osimertinib combination in EGFR mutant models, PC9 (EGFR ex19del) and NCI-H1975 (EGFR L858R/T790M).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S5 details the antitumor activity of MRTX0902 and avutometinib in human KRAS-MAPK pathway mutant tumor cell line-derived xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S5 details the antitumor activity of MRTX0902 and avutometinib in human KRAS-MAPK pathway mutant tumor cell line-derived xenograft models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Figure S4 shows levels of KRAS-MAPK pathway modulation associated with coadministration of MRTX0902 and adagrasib in the MIA PaCa-2 (KRAS G12C-mutant) model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S4 shows the antitumor activity of MRTX0902 and osimertinib in human EGFR-mutant tumor cell line-derived xenograft models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Supplementary Table S4 shows the antitumor activity of MRTX0902 and osimertinib in human EGFR-mutant tumor cell line-derived xenograft models.